Neuromodulation company pioneering the Neuspera Sacral Neuromodulation (SNM) System Neuspera Medical, Inc. announced on Thursday that it has named Bunty Banerjee as its first chief operating officer.

In the new role, Banerjee is to head activities in both R&D and operations, while working closely with all other functions, as Neuspera completes the US Food and Drug Administration (FDA) submission for regulatory approval of the Neuspera System to treat OAB symptoms and prepares for commercialisation.

Banerjee, a life sciences executive, has over 25 years of experience in the medical device industry, holding senior operational leadership positions at Omnicell, Philips Image Guided Therapy, Abbott and Boston Scientific. He has worked in senior leadership roles in enterprises ranging from early start-ups to Fortune 100 corporations.

Steffen Hovard, CEO of Neuspera Medical, said, 'Bunty is joining Neuspera at an incredibly exciting time for the company. We look forward to his contributions to the team as he deploys valuable skills and insights with the organisation.'